氨茶碱与多索茶碱治疗慢性阻塞性肺疾病的临床价值

Clinical value of aminophylline and doxofylline in the treatment of chronic obstructive pulmonary disease

目的探究氨茶碱与多索茶碱治疗慢性阻塞性肺疾病(COPD)的临床价值。方法选取2020年4月至2021年4月本院收治的90例COPD患者作为研究对象,按照随机数字表法分为对照组和观察组,每组45例。对照组应用氨茶碱治疗,观察组应用多索茶碱治疗,比较两组临床疗效、肺功能指标[第1秒用力呼气容积(FEV_(1))、用力肺活量(FVC)及FEV_(1)/FVC]、血气功能指标[动脉血氧分压(PaO_(2))、动脉血二氧化碳分压(PaCO_(2))]、不良反应发生率、生命质量及病情控制情况。结果观察组治疗总有效率(93.33%)高于对照组(77.78%),差异有统计学意义(P<0.05)。治疗前,两组FEV_(1)、FVC、FEV_(1)/FVC比较差异无统计学意义;治疗后,两组FEV_(1)、FVC、FEV_(1)/FVC均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。治疗前,两组PaO_(2)、PaCO_(2)比较差异无统计学意义;治疗后,两组PaO_(2)均高于治疗前,PaCO_(2)均低于治疗前,且观察组PaO_(2)高于对照组,PaCO_(2)低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义,经后期对症处理后均消失。治疗前,两组圣乔治呼吸问卷(SGRQ)、COPD评估测试(CAT)评分比较差异无统计学意义;治疗后,两组SGRQ评分均高于治疗前,CAT评分均低于治疗前,且观察组SGRQ评分高于对照组,CAT评分低于对照组,差异有统计学意义(P<0.05)。结论多索茶碱治疗COPD疗效显著,可明显提升患者肺功能,改善血气指标及呼吸功能,有效控制病情进展,安全性高,值得临床推广应用。

Objective To investigate the clinical value of aminophylline and doxofylline in the treatment of chronic obstructive pulmonary disease(COPD).Methods 90 patients with COPD admitted to our hospital from April 2020 to April 2021 were selected as the research subjects,and they were divided into control group and observation group according to random number table,with 45 cases in each group.The control group was treated with aminophylline,and the observation group was treated with doxofylline,the clinical efficacy,pulmonary function indexes(forced expiratory volume in one second[FEV_(1)],forced vital capacity[FVC]and FEV_(1)/FVC),blood gas function indexes(partial pressure of oxygen[PaO_(2)],partial pressure of carbon dioxide[PaCO_(2)]),adverse reaction rate,and quality of life and condition control were compared between the two groups.Results The total effective rate of the observation group(93.33%)was higher than that of the control group(77.78%),the difference was statistically significant(P<0.05).Before treatment,there was no significant difference in FEV_(1),FVC and FEV_(1)/FVC between the two groups;after treatment,FEV_(1),FVC and FEV_(1)/FVC of the two groups were higher than those before treatment,and the observation group were higher than the control group,and the differences were statistically significant(P<0.05).Before treatment,there was no significant difference in PaO_(2) and PaCO_(2) between the two groups;after treatment,PaO_(2) of the two groups was higher than that before treatment,PaCO_(2) was lower than that before treatment,and PaO_(2) in the observation group was higher than that in the control group,PaCO_(2) was lower than that in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups,disappeared after symptomatic treatment.Before treatment,there was no significant difference in St.George's respiratory questionnaire(SGRQ)and COPD assessment test(CAT)scores between the two groups;after treatment,the SGRQ scores of the two groups were higher than those before treatment,and the CAT scores were lower than those before treatment,and the SGRQ score in the observation group was higher than that in the control group,and the CAT score was lower than that in the control group,and the differences were statistically significant(P<0.05).Conclusion Doxofylline significant effect in the treatment of COPD,significantly improve pulmonary function,improve blood gas index and respiratory function,effective control of disease progression,high safety,worthy of clinical application.